{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:53:47Z","timestamp":1790016827086,"version":"4.0.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["R01 HL136395"],"award-info":[{"award-number":["R01 HL136395"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jbc.2025.110561","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:06:31Z","timestamp":1754431591000},"page":"110561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The urokinase receptor\/uPAR is a major effector of p53 gain-of-function mutations in gemcitabine-treated pancreatic ductal adenocarcinoma"],"prefix":"10.1016","volume":"301","author":[{"given":"Carlotta","family":"Zampieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourosh","family":"Kouhmareh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9361-179X","authenticated-orcid":false,"given":"Parnian","family":"Sartipdolagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1512-5581","authenticated-orcid":false,"given":"Pardis","family":"Azmoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Klemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Gonias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2025.110561_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jbc.2025.110561_bib2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2025.110561_bib3","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1101\/gad.1415606","article-title":"Genetics and biology of pancreatic ductal adenocarcinoma","volume":"20","author":"Hezel","year":"2006","journal-title":"Genes Dev."},{"key":"10.1016\/j.jbc.2025.110561_bib4","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3390\/cancers11121983","article-title":"p53-Mediated tumor suppression: DNA-damage response and alternative mechanisms","volume":"11","author":"Pitolli","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.jbc.2025.110561_bib5","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","article-title":"Understanding the complexity of p53 in a new era of tumor suppression","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.110561_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.607670","article-title":"Mutant p53 Gain-of-Function: role in cancer development, progression, and therapeutic approaches","volume":"8","author":"Alvarado-Ortiz","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jbc.2025.110561_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbamcr.2014.10.003","article-title":"Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine","volume":"1853","author":"Fiorini","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jbc.2025.110561_bib8","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/1878-0261.13161","article-title":"p53 mutations define the chromatin landscape to confer drug tolerance in pancreatic cancer","volume":"16","author":"Zampieri","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.jbc.2025.110561_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","article-title":"Mutant p53 as a guardian of the cancer cell","volume":"26","author":"Mantovani","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jbc.2025.110561_bib10","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1101\/gad.263202.115","article-title":"Mutant p53 cooperates with the SWI\/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells","volume":"29","author":"Pfister","year":"2015","journal-title":"Genes Dev."},{"key":"10.1016\/j.jbc.2025.110561_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41586-020-2541-0","article-title":"The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic","volume":"586","author":"Kadosh","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2025.110561_bib12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s13046-024-03232-3","article-title":"Selective metabolic regulations by p53 mutant variants in pancreatic cancer","volume":"43","author":"Caporali","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2025.110561_bib13","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1101\/gad.181685.111","article-title":"Mutant p53 cooperates with ETS2 to promote etoposide resistance","volume":"26","author":"Do","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.jbc.2025.110561_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ccr.2006.08.014","article-title":"Mutant p53 gain of function: the NF-Y connection","volume":"10","author":"Peart","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.110561_bib15","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ccr.2013.03.022","article-title":"Mutant p53 prolongs NF-\u03baB activation and promotes chronic inflammation and inflammation-associated colorectal cancer","volume":"23","author":"Cooks","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.110561_bib16","doi-asserted-by":"crossref","first-page":"C721","DOI":"10.1152\/ajpcell.00269.2021","article-title":"Plasminogen activator receptor assemblies in cell signaling, innate immunity, and inflammation","volume":"321","author":"Gonias","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.jbc.2025.110561_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s000180050497","article-title":"The plasminogen activation system in tumor growth, invasion, and metastasis","volume":"57","author":"Andreasen\u2217","year":"2000","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jbc.2025.110561_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2821","article-title":"Regulation of cell signalling by uPAR","volume":"11","author":"Smith","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jbc.2025.110561_bib19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nrm977","article-title":"uPAR: a versatile signalling orchestrator","volume":"3","author":"Blasi","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jbc.2025.110561_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.818616","article-title":"Modulation of cellular function by the urokinase receptor signalling: a mechanistic view","volume":"10","author":"Alfano","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jbc.2025.110561_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2018.00024","article-title":"Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, prognostic, and therapeutic applications","volume":"8","author":"Mahmood","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbc.2025.110561_bib22","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1242\/jcs.114.18.3387","article-title":"Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK\/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells","volume":"114","author":"Ma","year":"2001","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.jbc.2025.110561_bib23","doi-asserted-by":"crossref","first-page":"9388","DOI":"10.1038\/s41598-017-10062-1","article-title":"Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors","volume":"7","author":"Mauro","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2025.110561_bib24","doi-asserted-by":"crossref","first-page":"22825","DOI":"10.1074\/jbc.M109.023960","article-title":"Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling","volume":"284","author":"Jo","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2025.110561_bib25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1083\/jcb.200701092","article-title":"uPAR induces epithelial\u2013mesenchymal transition in hypoxic breast cancer cells","volume":"178","author":"Lester","year":"2007","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jbc.2025.110561_bib26","doi-asserted-by":"crossref","first-page":"8948","DOI":"10.1158\/0008-5472.CAN-10-1936","article-title":"Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells","volume":"70","author":"Jo","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2025.110561_bib27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1078-0432.CCR-10-2258","article-title":"Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis","volume":"17","author":"Kenny","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2025.110561_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.663225","article-title":"CRISPR\/Cas9 uPAR gene knockout results in tumor growth inhibition, EGFR downregulation and induction of stemness markers in melanoma and Colon carcinoma cell lines","volume":"11","author":"Biagioni","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbc.2025.110561_bib29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/0008-5472.CAN-14-2004","article-title":"A urokinase receptor\u2013bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma","volume":"75","author":"Wykosky","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2025.110561_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fphar.2015.00154","article-title":"Urokinase receptor and resistance to targeted anticancer agents","volume":"6","author":"Gonias","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jbc.2025.110561_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12967-022-03329-3","article-title":"Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer","volume":"20","author":"Zhai","year":"2022","journal-title":"J. Translational Med."},{"key":"10.1016\/j.jbc.2025.110561_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1535-6108(03)00162-4","article-title":"ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility","volume":"4","author":"Vial","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.110561_bib33","first-page":"1684","article-title":"ERKMAPK activity as a determinant of tumor growth and dormancy; regulation by p38SAPK1","volume":"63","author":"Aguirre-Ghiso","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2025.110561_bib34","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2025.110561_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/1177271917715443","article-title":"Prognostic impact of urokinase plasminogen activator receptor expression in pancreatic cancer: malignant versus stromal cells","volume":"12","author":"de Geus","year":"2017","journal-title":"Biomark Insights"},{"key":"10.1016\/j.jbc.2025.110561_bib36","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.3390\/cancers15051587","article-title":"Urokinase-type plasminogen activator receptor (uPAR) cooperates with mutated KRAS in regulating cellular plasticity and gemcitabine response in pancreatic adenocarcinomas","volume":"15","author":"Peng","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbc.2025.110561_bib37","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: new functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.110561_bib38","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1158\/0008-5472.CAN-21-3376","article-title":"Differential gain-of-function activity of three p53 hotspot mutants in vivo","volume":"82","author":"Xiong","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2025.110561_bib39","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/ijms21031102","article-title":"Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity","volume":"21","author":"Lee","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2025.110561_bib40","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbc.2025.110561_bib41","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1074\/jbc.273.3.1496","article-title":"Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein Kinase-1a\/p90 rsk that are inducible by MAPK","volume":"273","author":"Dalby","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2025.110561_bib42","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nrm2509","article-title":"The RSK family of kinases: emerging roles in cellular signalling","volume":"9","author":"Anjum","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jbc.2025.110561_bib43","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1074\/jbc.M008210200","article-title":"Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway\u2217","volume":"276","author":"Jost","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2025.110561_bib44","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1535-6108(02)00072-7","article-title":"EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma","volume":"1","author":"Liu","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.110561_bib45","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1074\/jbc.M210877200","article-title":"Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor","volume":"278","author":"Jo","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2025.110561_bib46","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/cas.13220","article-title":"Metabolic characterization of invaded cells of the pancreatic cancer cell line, PANC-1","volume":"108","author":"Fujita","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jbc.2025.110561_bib47","doi-asserted-by":"crossref","first-page":"21197","DOI":"10.1074\/jbc.M113.484576","article-title":"An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor \u03baB- and hypoxia-inducible factor 1\u03b1-MEDIATED up-regulation of CXCR4\u2217","volume":"288","author":"Arora","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2025.110561_bib48","doi-asserted-by":"crossref","first-page":"62177","DOI":"10.18632\/oncotarget.11405","article-title":"Gemcitabine enhances cell invasion via activating HAb18G\/CD147-EGFR-pSTAT3 signaling","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbc.2025.110561_bib49","first-page":"2369","article-title":"RhoB regulates uPAR signalling","volume":"125","author":"Alfano","year":"2012","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.jbc.2025.110561_bib50","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1006\/bbrc.2000.2531","article-title":"Regulation of urokinase receptor transcription by Ras- and rho-family GTPases","volume":"270","author":"Muller","year":"2000","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"10.1016\/j.jbc.2025.110561_bib51","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41467-023-36296-4","article-title":"Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment","volume":"14","author":"Werba","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2025.110561_bib52","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lfs.2011.05.010","article-title":"Generation, function and diagnostic value of mitochondrial DNA copy number alterations in human cancers","volume":"89","author":"Yu","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.jbc.2025.110561_bib53","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/0008-5472.CAN-22-1742","article-title":"Systematic comparison of pancreatic ductal adenocarcinoma models identifies a conserved highly plastic basal cell state","volume":"82","author":"Pitter","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2025.110561_bib54","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1186\/s12964-024-01957-4","article-title":"The impact of epithelial-mesenchymal transition (EMT) induced by metabolic processes and intracellular signaling pathways on chemo-resistance, metastasis, and recurrence in solid tumors","volume":"22","author":"Liaghat","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.jbc.2025.110561_bib55","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1038\/s41598-018-21358-1","article-title":"The urokinase receptor induces a mesenchymal gene expression signature in glioblastoma cells and promotes tumor cell survival in neurospheres","volume":"8","author":"Gilder","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2025.110561_bib56","doi-asserted-by":"crossref","first-page":"17758","DOI":"10.1074\/jbc.M601812200","article-title":"Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels","volume":"281","author":"Alfano","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2025.110561_bib57","first-page":"437","article-title":"Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed","volume":"37","author":"Cortes-Dericks","year":"2010","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jbc.2025.110561_bib58","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/jop.12046","article-title":"Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells","volume":"42","author":"Huang","year":"2013","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.jbc.2025.110561_bib59","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cellsig.2012.05.011","article-title":"A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen","volume":"24","author":"Eastman","year":"2012","journal-title":"Cell Signal."},{"key":"10.1016\/j.jbc.2025.110561_bib60","doi-asserted-by":"crossref","first-page":"15984","DOI":"10.1073\/pnas.1113416108","article-title":"Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells","volume":"108","author":"Hu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110561_bib61","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/cancers13081838","article-title":"Plasmin and plasminogen system in the tumor microenvironment: implications for cancer diagnosis, prognosis, and therapy","volume":"13","author":"Bharadwaj","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jbc.2025.110561_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.835929","article-title":"Cancer progression gene expression profiling identifies the urokinase plasminogen activator receptor as a biomarker of metastasis in cutaneous squamous cell carcinoma","volume":"12","author":"Minaei","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbc.2025.110561_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115229","article-title":"RSK inhibitors as potential anticancer agents: discovery, optimization, and challenges","volume":"251","author":"Sun","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jbc.2025.110561_bib64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncb2173","article-title":"p53 regulates epithelial\u2013mesenchymal transition and stem cell properties through modulating miRNAs","volume":"13","author":"Chang","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jbc.2025.110561_bib65","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1007\/s11033-021-06706-1","article-title":"Crosslink between p53 and metastasis: focus on epithelial-mesenchymal transition, cancer stem cell, angiogenesis, autophagy, and anoikis","volume":"48","author":"Babaei","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.jbc.2025.110561_bib66","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/onc.2012.334","article-title":"Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis","volume":"32","author":"Dong","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2025.110561_bib67","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.trecan.2019.11.004","article-title":"Mutant p53 on the path to metastasis","volume":"6","author":"Tang","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jbc.2025.110561_bib68","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.97422","article-title":"Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma","author":"Schofield","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jbc.2025.110561_bib69","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/0008-5472.CAN-10-2267","article-title":"Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53","volume":"71","author":"Timpson","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2025.110561_bib70","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cell.2014.01.066","article-title":"Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor \u03b2 signaling","volume":"157","author":"Weissmueller","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2025.110561_bib71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","article-title":"SCANPY: large-scale single-cell gene expression data analysis","volume":"19","author":"Wolf","year":"2018","journal-title":"Genome Biol."},{"key":"10.1016\/j.jbc.2025.110561_bib72","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41587-021-01206-w","article-title":"A python library for probabilistic analysis of single-cell omics data","volume":"40","author":"Gayoso","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jbc.2025.110561_bib73","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1016\/j.cell.2023.11.026","article-title":"Automatic cell-type harmonization and integration across human cell atlas datasets","volume":"186","author":"Xu","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2025.110561_bib74","doi-asserted-by":"crossref","first-page":"baz046","DOI":"10.1093\/database\/baz046","article-title":"PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data","volume":"2019","author":"Franz\u00e9n","year":"2019","journal-title":"Database"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825024123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825024123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:20:19Z","timestamp":1772814019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925825024123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":74,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0021925825024123"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2025.110561","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The urokinase receptor\/uPAR is a major effector of p53 gain-of-function mutations in gemcitabine-treated pancreatic ductal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2025.110561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology\u00e9","name":"copyright","label":"Copyright"}],"article-number":"110561"}}